Filing Flows › Celldex Therapeutics (CLDX) › Q2 2026
Celldex Therapeutics (CLDX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Celldex Therapeutics (CLDX) reported revenue of $22K for the second quarter 2026 (Q2 2026), -97% from a year earlier and +47% from the quarter before.
Celldex Therapeutics, Q2 2026: revenue $22K (-97% year over year), net loss $73.5M, operating cash flow −$57.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22K | +47% | -97% |
| Operating profit | −$80.6M | — | — |
| Net earnings | −$73.5M | — | — |
| Operating cash flow | −$57.4M | — | — |
What changed
Revenue was $22K in Q2 2026, down 97% year over year and up 47% from the previous quarter. Contracts and grants was the largest line at 68% of revenue. Contracts and grants lost $708K year over year (down 98%), 100% of the total change.
Operating costs exceeded revenue by $80.6M, an operating margin of -366468.2%. Total costs grew 25% against a revenue fall of 97%. The fastest-growing cost line was General & admin (+26%). The quarter ended with a net loss of $73.5M, narrower than the previous quarter's $78.7M loss.
Operating cash flow was −$57.4M. Non-cash charges added back $902K of depreciation and amortization and $8.4M of share-based compensation. Working capital and other items added $6.8M. Capital expenditures of $3.2M exceeded it, leaving free cash flow of −$60.6M.
Questions
What was Celldex Therapeutics' revenue in the second quarter 2026?
Celldex Therapeutics (CLDX) reported revenue of $22K for the second quarter 2026 (Q2 2026), -97% from a year earlier and +47% from the quarter before.